Chicago Atlantic Real Estate Finance, Inc. (REFI) Earnings Call Transcript & Summary

March 22, 2022

NASDAQ US Real Estate Mortgage Real Estate Investment Trusts (REITs) earnings

Earnings Call Speaker Segments

Tripp Sullivan

executive
#1

Thanks so much, and good morning. It's great to have everyone join Chicago Atlantic Real Estate Finance's conference call, where we'll go over what the company achieved in 2021's fourth quarter. Joining us on this call are John Mazarakis, our Executive Chairman; Tony Cappell, Chief Executive Officer; Andreas Bodmeier, Co-President and Chief Investment Officer; and Lindsay Menze, Chief Financial Officer. This morning, our earnings press release came out with our results, and you can locate it in the Investor Relations area of our website, together with our supplemental that was filed with the SEC. Shortly after this call wraps up, a replay will be accessible, and it will remain available through March 29, 2022. The earnings press release contains the numbers you'll need to access that replay; if you happen to be listening to the replay, please note that everything we say here reflects today, March 22, 2022, and nothing will be revised after this call concludes. As part of this call, some of the comments and statements we make could be considered forward-looking statements under the meaning set forth by the securities laws, including statements about how our portfolio will perform going forward, our pipeline of possible loans and other investments, upcoming dividends, and financing activities. Every forward-looking statement reflects Chicago Atlantic's judgment as of the date of this conference call and carries risk and uncertainties that could make actual results differ materially from what we currently expect. We encourage investors to thoroughly examine the various disclosures the company has made, including the risks and other information found in the Company's filings with the SEC. Additionally, we'll touch on certain non-GAAP measures, including but not limited to distributable earnings and adjusted distributable earnings. You can find definitions of these non-GAAP measures and reconciliations to the most comparable GAAP measures in our filings with the SEC. At this point, I'll hand the call over to John Mazarakis. Please go ahead.

John Mazarakis

executive
#2

Thank you, Tripp. Hello everybody, and we appreciate you being with us this morning. Since this marks the initial earnings call following our IPO completion in early December, I want to extend a welcome to each of our new investors and analysts. Getting here has required a great deal of effort, and we are enthusiastic about what lies in front of us. Given that under 1 month separates our IPO at the close of Q4 from now, the true gauge of the strength of our beginning — what we have constructed — how powerful a launch we have achieved can be seen in our portfolio's expansion, the appealing yields we are producing, and the strong pipeline of fresh loan originations. We will spend a large portion of today's call addressing all of these subjects, along with where the industry stands and what we intend for our capital structure. Prior to that, I want to highlight a few of our financial results for the quarter and so far in March; we have been increasing our loan commitments at inception of the REIT Q2 2021 we had $72 million in commitments; that figure for loan commitments expanded to $192 million at IPO and $235 million at the close of 2021. As of March 17, our commitments total $324 million. From the IPO through March 17, we have funded $115 million of new and existing commitments. With that, we have put all IPO proceeds to work, which places us ahead of schedule in deploying the IPO proceeds and starting to draw on our revolving credit facility. Thanks to this portfolio expansion, we could report $0.57 of earnings and $0.61 of adjustable distributable earnings for Q4. The Q4 results, along with an active beginning to the year, also allowed the Board to declare a $0.26 dividend in Q4 and then raise it in Q1 by 54% to $0.40 per share; now, let's discuss what drew us to the cannabis market in the first place. 4 years ago, we saw that an opportunity existed to deliver an institutional lending approach to a sector that had historically found it difficult to obtain capital. By institutional approach, I mean bringing to the young cannabis industry the disciplines that are assumed in all of direct lending, including rigorous credit reviews, strict underwriting guidelines, deep operator evaluations, enterprise value analysis, as well as other methods of perfecting collateral. Our goal was not to invent a new lending model. Rather, we simply concentrated on applying what has been a proven approach to an industry that badly required it. With slightly more than $1 billion in closed facilities, the majority of which have been in cannabis, we have built a solid track record and benefited from being an early entrant in this space. The reality is, a track record like this cannot be built without a strong team, and ours ranks among the best in the industry. Tony's spent more than 15 years working in banking, and over the course of his career at Wells Fargo and SteelGate Capital, he's closed in excess of $5 billion worth of loans. At our firm, Andreas leads investment activities and has underwritten cannabis credit transactions totaling more than $500 million. His robust background in research and consulting is a real asset for our risk management work. Before he came aboard, Peter ran the cannabis lending practice at BC Partners Credit, and he too brings a solid underwriting background. My own roots are in operations — I've built companies from scratch and worked as a real estate developer and owner. Our backgrounds are varied but they fit together well, and we're supported by a group of more than 30 investment and management professionals who've been instrumental in establishing the Chicago Atlantic name within cannabis; that's what I concentrate on daily, making sure the right individuals are in place, the culture is right, and the REIT is fully integrated with the Chicago Atlantic originations platform, and I aim to keep enhancing the solid reputation we've earned as a trustworthy source of capital and to expand alongside the top operators in this sector. One more thing that drew us to cannabis is how far from mature it is. In the past I've characterized it as perhaps being in the second inning of its development. With an industry of this kind, getting an accurate read on the true size of the addressable market can be tricky at times. We, along with others in the sector, have estimated the present size of legal, state-regulated markets at $25 billion in top line retail revenue, with a multiple of that figure spread across the whole value chain. I believe we're all aware it's considerably bigger once you account for the illicit market, which over time will ultimately turn legal. Once you make adjustments for that unavoidable shift, our view is that it's genuinely a $100 billion industry on the retail side alone. Our presentation contains stats showing the industry might match beer, spirit, and wine by 2030, which brings about significant growth potential and a need for capital. This sector isn't the Wild West any longer. The true winners here will be operators possessing a proven and disciplined approach — the ones who grasp unit economics, manufacturing scale, and multi-unit retail operations. As Andreas will detail later, in reviewing the opportunities in our pipeline, we can swiftly identify the operators meeting our stringent criteria, along with those who probably never will. Our belief is that strong operators will reap rewards over the long term, and a shakeout will persist. Looking across our portfolio, our capital deployment focus is obvious; we've mainly aimed at Limited License states with vertically integrated operators. Though we're open to opportunities west of the Mississippi, our preference is to begin in states licensed for medical use and then expand inside them as many of those states move to adult use. One of the largest obstacles this industry faces is the regulatory landscape, and we know the dynamics in every state very well, along with what proposals are on the table. Now, while the true potential of this market will ultimately be unlocked by federal legalization, passage of the Safe Banking Act, and a change to Section 280E of the Internal Revenue Code, our set of opportunities isn't predicated on any of those things happening soon. Once the Biden-Harris administration came in, people speculated about full legalization and swift passage of the Safe Banking Act. When that failed to materialize, we watched public market valuations for cannabis operators fall sharply, and their access to equity capital either got shut off or all at once turned far pricier than that. All kinds of inflationary pressures — COVID, Ukraine, the global supply disruption, plus the Federal Reserve's moves — made this uncertain environment worse. What you have to keep in mind is that these operators are in growth mode. Demand for their products hasn't shown any indication of slowing, not even during the pandemic, when it in fact sped up, and they must put money into production, cultivation and retail; that need for capital is best served by partnering with us; we don't benefit from turmoil in the public equity market, but it's plainly a net positive for us in both the near and long term. Tony, why don't you pick it up from here?

Anthony Cappell

executive
#3

Appreciate that, John. Morning, everybody. On our IPO road show back in December, we laid out a plan, and we've carried it out to the letter. The priorities were expanding our pipeline, deploying the IPO funds at returns and collateral coverage in line with what our current portfolio holds, moving on that pipeline as quickly as we can, and extending the first mover advantage John mentioned a moment ago. Before I walk through how we executed in Q4, year to date, and Q1, let me take a few moments on the things that set us apart and explain these results. It begins with the way we generate new loan originations. Throughout the Chicago Atlantic platform, seven investment professionals are devoted to originating new loans. Our view is that we've brought the standard structure of credit lending into the cannabis space. Most of our rivals in cannabis get their deals through syndication from investment banks, or sometimes they join facilities where we are the lead. A community bank or another lender may hold a local relationship with an operator, yet usually they lack the cannabis expertise to genuinely grasp what they are underwriting or what their borrower requires. Beyond the inbounds that come from the brand recognition we've built, we receive referrals from borrowers, brokers, and banking relationships. Whenever we evaluate new borrowers and loan opportunities, four criteria guide us. The state comes first. As John said earlier, we concentrate mainly on the area east of the Mississippi. That will remain our emphasis, though it doesn't stop us from lending to the best in class operators in the more efficient markets. Next, we favor a medical state over an adult-use state, since a transition to adult-use drives revenue growth and therefore EBITDA growth, which strengthens our borrower's credit worthiness and raises the value of the license and business underneath. Third, cash flow matters to us. Although all but a small number of our loans carry underlying coverage through real estate, we underwrite our borrowers based on their capacity to generate the bottom line and run at a profit. Finally, we seek strong collateral coverage, covering real estate, AR, equipment, personal guarantees, and other assets that can be more intangible in nature. We'd rather not reveal too much of our secret sauce, but we hold proprietary methods for perfecting collateral and liens in an industry where limitations exist when you have to exercise your rights and remedies in a workout. Luckily, we haven't faced that situation so far, since every loan is performing and a payment default has yet to occur anywhere on the platform. Even so, we underwrite that risk on a regular basis, and strong real estate coverage, equity pledges, and all asset liens sit behind our loans. One standout deal we closed during Q1 involves Sanctuary Medicinals, a vertically integrated Florida operator. We provided them a senior secured delay draw term loan of $25 million, and those funds went toward adding more canopy as well as pushing forward with dispensary growth. At the time of closing, 6 dispensaries were up and running, and they anticipate launching another 10 over the term's initial year. Why is this such a solid loan? First, their home state of Florida is a limited license jurisdiction, and its medical program ranks among the strongest anywhere in the nation. Registered patients there exceed 675,000, a figure that keeps climbing. On top of that, adult-use legalization is anticipated in Florida within a handful of years, and given its expanding population plus a powerful tourism sector, that would form one of the biggest markets in America. Second, real estate coverage currently stands above two times. Once every piece of collateral is factored in, we calculate an LTV below 35%. Third, Sanctuary Medicinals boasts an excellent management group whose cannabis operating record is well proven. Finally, every dollar of their capital goes toward accretive purposes, strengthening our collateral along with the borrower's future cash flows and reducing risk across the life of the term. One more important distinction: our loan structures make us the sole debt source for a borrower, and the REIT serves as lead or co-lead on the credit facility. That safeguards our collateral while letting us keep a strong bond with borrowers and expand alongside them. We likewise never retrade, something unusual in a sector where retrading happens all the time. What we put in our term sheets is exactly what we deliver. In our view, that reputation, paired with our substantial committed footprint in the industry and our capacity to grow together with borrowers, positions us as the preferred lender for top-tier cannabis operators. A prime indicator of our reputation is how consistently strong our loan origination pipeline stays. As of today, that pipeline sits at roughly $979 million, made up of opportunities involving both current and prospective borrowers across limited license states, and these carry risk profiles and yields in line with what's already in the portfolio. As of last week, we've funded close to $115 million in loans within the REIT since the IPO. That's a remarkable beginning to our new chapter as a public company, and we intend to keep building on it. Turning to the rest of the year, we aren't giving a specific 2022 loan origination target right now, though I'd point out this mostly hinges on our ability to tap appealing capital sources. Funding $115 million into the REIT in just over three months is a brisk clip, yet we're careful about sustaining that clip using capital that would dilute our current investors. Andreas is going to take us through the capital plan in a moment, but our expectation is that we'll stick with what we laid out at the time of our IPO: drawing on the credit facility and potentially doing a debt offering before returning to the public equity markets. There's another commitment from the IPO that we've now made good on, and that's delivering dividend growth for our investors. At year end, we declared our first dividend, for Q4, at $0.26 per share, and adjusted distributable earnings covered it, even if you adjust for the fully loaded share count of 17.5 million. As this morning's earnings release noted, the Board has declared a Q1 dividend of $0.40 per share, which is a 54% increase over Q4, and at Friday's closing price that works out to an annualized yield of 9.4%; and although we haven't set a specific payout target, our expectation is that it would be at least 85%; now Andreas will take us through our investments and capital plan.

Andreas Bodmeier

executive
#4

Thanks, Tony, and good morning, everyone. We did a solid job laying out our investment activity in both the earnings release and the supplemental, and I'll touch on those documents while adding a bit of extra color. When we went public, we disclosed a portfolio of 17 loans with $192 million in commitments, funded and unfunded combined, that carried a weighted average yield of 17.1%. Come December 31, that portfolio had expanded to $235 million in total loan commitments spread across 21 portfolio companies, at a weighted average yield of 18.6%. The IRR came in somewhat above what we had anticipated, driven by a high-yielding bridge loan that came ahead of a bigger facility in January 2021. As of March 17, total loan commitments had reached $324 million spanning 23 portfolio companies, with a weighted average yield of 17.3%. That number aligns better with what we expect moving forward. To recap what we've accomplished since the IPO, that works out to $115 million in total loan fundings from new commitments as well as existing ones. Quite a beginning, though there's a great deal more we intend to achieve. Our portfolio remains solid. Every loan is current and performing. And as we all know, the Fed raising rates 25 basis points last week is a hot topic. I'd point out that 57% of our portfolio is floating rate today, which has let us handle the effects of rising rates. As John mentioned earlier, the current environment hasn't reduced demand for debt capital; if anything, it has boosted it, and we're confident we'll keep sourcing new opportunities offering the yields we've been targeting. We've also thought through how inflation and rising interest rates might affect our borrowers. Through our borrowers, we've seen construction costs rise 10% to 30% along with continuing delivery delays. We have a seasoned real estate and cannabis development team that reviews our borrowers' construction efforts, and we underwrite so that our capital is shielded from construction execution risk; in our view, higher construction costs raise the value of the real estate collateral we already hold. And across the industry, an environment of rising interest rates calls for a focus on underwriting to cash flow generation, and in the end rewards conservatively levered and established operators. Finally, I want to discuss our capital plans for the year. Now that we've fully deployed our IPO proceeds, our next step matches what we described at our IPO. We intend to draw on our senior bank credit facility; in mid December, we increased that facility from 10 million to 45 million, with an additional bank joining it. Now while we currently have full availability on the existing line, we're actively negotiating to increase it once more over the coming weeks. The upcoming and future increases to the credit facility ought to give us additional runway to keep capturing new opportunities from our pipeline. From the start, what we've aimed for is employing this facility, and potentially a bond or net that offering, to hit our objective of just 0.5 turns of leverage by the time the year ends. Being conservative comes naturally to us, so our plan is to operate with leverage below what's typical across the mortgage REIT sector, all while staying mindful of how dilution affects our existing shareholders. With that said, I'll hand things over to Lindsay so she can walk through our financials.

Lindsay Menze

executive
#5

Thank you, Andreas, and hello everybody. To begin, please direct your attention to the supplemental information that was filed earlier today, which offers more detailed disclosures on top of those mentioned in these prepared remarks. Having operated as a public company for under one month, the Q4 results can't yet be seen as indicative of the performance we're capable of, though they did line up with what we anticipated in our S11. The steps taken since our IPO closed have positioned us nicely to produce even stronger results as the year goes on. Instead of reading through every financial result this morning, I'd like to highlight a handful of moving pieces in our Q4 print. Like I said before, our loan book expanded a lot this quarter, especially in December, when we began deploying the money raised in the IPO. As a result, the $5.8 million we earned in total interest income doesn't yet capture the benefit of having those funds fully at work. Deployment of the IPO proceeds is running well ahead of our timeline, with the advantage building in Q1 and the complete impact anticipated to appear in Q2. Quarterly expenses came in at almost the same level as what we spent across the entire year, since we booked management fees for the first time, along with roughly $63,000 in organizational costs and $148,000 tied to CECL reserves — both of which we added back when figuring adjusted distributable earnings. We came in under budget on organizational costs. Looking ahead, because our growth has outpaced what we planned, we anticipate G&A landing somewhere between $2.5 million and $3 million. The 10-K filing, complete with the footnotes that explain this, isn't due until the 31st, so I'll walk you through some specifics on the CECL reserves now. Under ASC 326, we booked a $148,000 provision for current expected credit losses during Q4. When arriving at that reserve figure, we observed that real estate fully secures 92% of the portfolio, while the remaining 8% carries limited or no real estate collateral. As of December 31, 2021, real estate collateral coverage across our portfolio averaged 2.2x. Every one of our loans is backed by both the borrower's equity pledges and liens on all assets. Once those are taken into account, along with the other adjustments spelled out in our S11, adjusted distributable earnings came to $0.61 per share in Q4. The weighted average share count we used for Q4 captured just 21 days of IPO share impact. In Q1, we'll feel the bulk of the effect from the 17.8 million shares outstanding following the offering and the greenshoe exercise in January 2022. Book value stood at $15.13 per common share as of December 31. Operator, we're ready for questions now.

Aaron Hecht

analyst
#6

Morning, everybody, and congratulations on getting your first earnings call done — I appreciate you fielding my questions. Tony, you mentioned that with the $0.40 dividend, the payout ratio for the first quarter would come in at no less than 85%. Which metrics sit in the denominator when you calculate that? Do you mean GAAP earnings, distributable, and if distributable is what you're using, are incentive fees in there or left out?

Anthony Cappell

executive
#7

Aaron, that 85% or higher figure applies to distributable earnings, and it reflects our outlook for the year. In Q1, we essentially paid out 100%, though going forward you'd anticipate that number coming down.

Aaron Hecht

analyst
#8

All right, and as for the distributable — does that figure come before incentive fees, or after they've been applied?

John Mazarakis

executive
#9

Andreas, are you able to hear me?

Andreas Bodmeier

executive
#10

That figure excludes incentive fees.

Aaron Hecht

analyst
#11

Excludes incentive fees, got it. Moving to the second point about leverage, you mentioned heading toward one half churn, and clearly you're deploying capital at a very fast pace. Once you move beyond that one half churn threshold, what would be your first consideration? Would the equity markets be your preference? Would you consider accepting a higher leverage pay level? How would you evaluate your capital options at that stage?

Andreas Bodmeier

executive
#12

There's substantial interest we're observing in our bank credit facilities. So if we can expand that beyond $100 million, then we'd opportunistically weigh a bond offering, and we might sit temporarily above that half a churn of leverage, prior to returning to the equity markets, which would subsequently restore it to our target ratio.

Aaron Hecht

analyst
#13

All right, and one final item, if that's okay. On the term sheets that have been signed, what do the yields look like?

Anthony Cappell

executive
#14

As far as yield goes, we have not observed any compression there. Essentially, as we mentioned at the time of the IPO, there are essentially two categories of loans we handle. One category essentially represents the deals that are heavily brokered, the top 5 to 10 MSOs. And then, the area where we concentrate our bread and butter is largely the single state, dual state operators that have performed very well with ample collateral and cash flow. So we keep concentrating on those operators, and at present we have not truly witnessed any compression in rates.

Aaron Hecht

analyst
#15

That's great, thanks for that, John. Nice work so far, everyone — I'll get back in line.

Mark Smith

analyst
#16

Hey folks, first thing I'd like to discuss is the industry a bit. So, you mentioned states with limited licenses and mostly being east of the Mississippi — could you share what industry trends you're seeing, especially in the markets where you're active?

Andreas Bodmeier

executive
#17

One thing we're all expecting and looking forward to is New Jersey going Rec. That's something we've been anticipating. Other trends show up in Massachusetts and Michigan, where there's a bit of compression. I'd say those markets don't really reflect the limited nature of other eastern states. So there, our focus is on the top tier operators who've targeted their cost per pound, and that's been our strategy.

Mark Smith

analyst
#18

All right, and a moment ago you both touched on this, but let's get into yield to maturity across this year — that 17.3. Should we anticipate some tightening eventually, or given rates climbing and that upward shift? Perhaps give the broad view on how you see it for this year?

Andreas Bodmeier

executive
#19

Yeah, no, what I'd say is at present those will hold steady for a good while. Clearly, since more than half our loans carry floating rates, there's going to be an uplift from that. Then, looking at the medium and longer term, my expectation is that tightening would occur, yet for the initial year at minimum, the foreseeable horizon within the current pipeline, it lines up with what sits in our portfolio.

Mark Smith

analyst
#20

Great. Then my final question — when we consider how the portfolio will grow over the remainder of the year, could you discuss your mix, or perhaps the mix you anticipate, between new borrowers and existing relationships?

Andreas Bodmeier

executive
#21

We currently have roughly $40 million of future fundings via facilities already in place, plus approximately $115 million in our underwriting pipeline, which includes signed term sheets and deposits. Those ratios should, more or less, stay unchanged.

Mark Smith

analyst
#22

Great. Thank you, guys.

Andreas Bodmeier

executive
#23

Thank you.

John Mazarakis

executive
#24

Thanks for that, and I appreciate everyone being here this morning. We're ready to take any follow-up questions you might have. Thanks once more.

Operator

operator
#25

So that brings us to the end of today's call, everyone. We appreciate you taking part, and at this point you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Chicago Atlantic Real Estate Finance, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Chicago Atlantic Real Estate Finance, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chicago Atlantic Real Estate Finance, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.